Hojjat-Farsangi, Mohammad and Ghalamfarsa, Ghasem and Kazemi, Mohammad Hossein and Raoofi Mohseni, Sahar and Masjedi, Ali and Azizi, Gholamreza and Yousefi, Mehdi and Jadidi-Niaragh, Farhad (2019) CD73 as a potential opportunity for cancer immunotherapy. Expert Opinion on Therapeutic Targets, 23 (2). pp. 127-142.
Full text not available from this repository.Abstract
Introduction: Cancer cells apply various mechanisms to induce and enhance immune escape. The complex network of immune-response modulating factors in the tumor microenvironment is a reason for the difficulties encountered when attempting to treat many cancers. Adenosine is a potent immune-modulating factor that can be generated through the degradation of ATP by cooperative action of NTPDase1 (CD39) and ecto-5ʹ-nucleotidase (CD73) molecules. Overexpression of CD73 on tumor and immune cells leads to the presence of a high concentration of this factor in the tumor region. Upregulation of CD73 is associated with the overproduction of adenosine; it suppresses antitumor immune responses and helps proliferation, angiogenesis, and metastasis. Areas covered: We attempt to clarify the immunobiology of CD73 in association with its role in cancer development, angiogenesis, and metastasis. Moreover, we have reviewed CD73-targeting studies and highlighted CD73 as a potent target for cancer immunotherapy. Expert opinion: It seems that blockade of CD73, in combination with immune checkpoint inhibitors such as anti-PD-L1 and anti-CTLA-4, can be a novel promising therapeutic strategy that can be evaluated in the future trials.
| Item Type: | Article |
|---|---|
| Subjects: | QW Microbiology and Immunology |
| Divisions: | Faculty of Medicin > Department of Immunology and Allergy |
| Depositing User: | محسن زارعی |
| Date Deposited: | 17 Apr 2019 07:45 |
| Last Modified: | 17 Apr 2019 07:45 |
| URI: | http://eprints.bpums.ac.ir/id/eprint/7796 |
Actions (login required)
 |
View Item |
